Don’t miss the upcoming Learning Theater sponsored by Savara
| Estimated time to read:
The following content is part of a paid sponsorship and is not an endorsement by CHEST nor does it reflect the views or opinions of CHEST.
Join Bruce C. Trapnell, MD, for an update on autoimmune pulmonary alveolar proteinosis (aPAP), covering the cardinal manifestations of the disease, burden of illness, and treatment landscape.
Following the presentation, Dr. Trapnell will moderate a panel discussion incorporating clinical insights from his practice with the lived experiences of Eric and Karli, patients living with aPAP.
Date: Tuesday, October 20
Time: 12:30 PM–1:15 PM MST
Location: Learning Theater 4 inside the Exhibit Hall
Undiagnosed aPAP can increase clinical burden1,2
It takes an average of 18 months for someone to be diagnosed accurately with aPAP.3
- Common chronic pulmonary symptoms
- An abnormal CT scan
- Pulmonary infections that are refractory to treatment
Then, it’s time to consider testing for GM-CSF autoantibodies.3,6
For more details, visit Booth #801 or click the button below.
This is a non CME event and does not qualify for CME, CE, or MOC credit. This event is not part of the official CHEST Annual Meeting 2026 conference sessions. This event is not an endorsement by CHEST and does not reflect the views or opinions of CHEST.
CT=computerized tomography; GM-CSF=granulocyte macrophage colony stimulating factor; PAP=pulmonary alveolar proteinosis.
References: 1. Data on file. REF-00012. Savara Inc. 2023. 2. Carey B, Chalk C, Stock J, et al. A dried blood spot test for diagnosis of autoimmune pulmonary alveolar proteinosis. J Immunol Methods. 2022;511:113366. doi:10.1016/j.jim.2022.113366. 3. Ataya A, Knight V, Carey BC, Lee E, Tarling EJ, Wang T. The role of GM-CSF autoantibodies in infection and autoimmune pulmonary alveolar proteinosis: a concise review. Front Immunol. 2021;12:752856. doi:10.3389/fimmu.2021.752856. 4. McCarthy C, Avetisyan R, Carey BC, Chalk C, Trapnell BC. Prevalence and healthcare burden of pulmonary alveolar proteinosis. Orphanet J Rare Dis. 2018;13(1):129-133. doi:10.1186/s13023018-0846-y. 5. Miyashita K, Hozumi H, Inoue Y, Suzuki T, Suda T. Nationwide survey of adult patients with pulmonary alveolar proteinosis using the National Database of designated intractable diseases of Japan. Respir Investig. 2023;61(3):364-370. doi:10.1016/j.resinv.2023.02.011. 6. McCarthy C, Kokosi M, Bonella F. Shaping the future of an ultra-rare disease: unmet needs in the diagnosis and treatment of pulmonary alveolar proteinosis. Curr Opin Pulm Med. 2019;25(5):450-458. doi:10.1097/MCP.0000000000000601.
